Nektar Therapeutics (NKTR)
Nektar Therapeutics
455 Mission Bay Boulevard South
San Francisco, CA 94158
United States
415 482 5300
https://www.nektar.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 137
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Howard W. Robin | CEO, President & Director | 1.83M | N/D | 1953 |
| Mr. Mark A. Wilson | Senior VP, Chief Legal Officer & Secretary | 749.99k | N/D | 1972 |
| Dr. Jonathan Zalevsky Ph.D. | Chief Research & Development Officer | 1.25M | N/D | 1975 |
| Ms. Sandra A. Gardiner | Interim Chief Financial Officer | N/D | N/D | 1966 |
| Vivian Wu | Director of Investor Relations & Corporate Affairs | N/D | N/D | N/D |
| Mr. Robert Bacci | Senior Vice President of Human Resources & Facilities Operations | N/D | N/D | N/D |
| Ms. Jennifer Ruddock | Chief Business Officer | N/D | N/D | N/D |
| Dr. Mary Tagliaferri L.Ac., M.D. | Chief Medical Officer | N/D | N/D | 1966 |
Descripción
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.
Gestión corporativa
La calificación ISS Governance QuickScore de Nektar Therapeutics a partir del 1 de abril de 2024 es 6. Las puntuaciones principales son Auditoría: 8; Junta: 7; Derechos del accionista: 2; Compensación: 8.
